Rocket Pharmaceuticals (RCKT) Capital Expenditures (2015 - 2026)
Rocket Pharmaceuticals (RCKT) reported Capital Expenditures of $93000.0 for Q1 2026, up 82.35% on a YoY basis from $51000.0 in Q1 2025, and up 16.25% sequentially from $80000.0 in Q4 2025.
Rocket Pharmaceuticals (RCKT) Capital Expenditures (2015 - 2026) Analysis & Trends
Rocket Pharmaceuticals (RCKT) has 12 years of Capital Expenditures data on file, last reported at $93000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures rose 82.35% year-over-year to $93000.0; the trailing twelve-month figure through Mar 2026 stood at $482000.0 (down 87.57% YoY), and the FY2025 full-year result was $440000.0, down 92.49% from the prior year.
- Capital Expenditures rose to $93000.0 in Q1 2026, from $80000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $14.8 million in Q4 2023 to a low of -$3.7 million in Q3 2024.
- A 5-year average of $1.5 million and a median of $405000.0 in 2023 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures soared 552.94% in 2023 and slumped 1013.58% in 2024, its largest moves.
- Tracing RCKT's Capital Expenditures over 5 years: stood at -$3.3 million in 2022, then soared by 552.94% to $14.8 million in 2023, then tumbled by 62.1% to $5.6 million in 2024, then tumbled by 98.57% to $80000.0 in 2025, then increased by 16.25% to $93000.0 in 2026.
- Business Quant data shows RCKT's Capital Expenditures at $93000.0 in Q1 2026, $80000.0 in Q4 2025, and $360000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Rocket Pharmaceuticals | 357.93 Mn | 357.93 Mn | - | 93,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 93,000.00 |
| Mar 31, 2026 | 93,000.00 |
| Dec 31, 2025 | 80,000.00 |
| Dec 31, 2025 | 80,000.00 |
| Sep 30, 2025 | 360,000.00 |
| Sep 30, 2025 | 360,000.00 |
| Jun 30, 2025 | -51,000.00 |
| Jun 30, 2025 | -51,000.00 |
| Mar 31, 2025 | 51,000.00 |
| Mar 31, 2025 | 51,000.00 |
| Dec 31, 2024 | 5.60 Mn |
| Dec 31, 2024 | 5.60 Mn |
| Sep 30, 2024 | -3.70 Mn |
| Sep 30, 2024 | -3.70 Mn |
| Jun 30, 2024 | 1.93 Mn |
| Jun 30, 2024 | 1.93 Mn |
| Mar 31, 2024 | 2.04 Mn |
| Mar 31, 2024 | 2.04 Mn |
| Dec 31, 2023 | 14.77 Mn |
| Dec 31, 2023 | 14.77 Mn |